Noah M. Hahn, M.D.

Associate Professor of Medicine
Department of Oncology and Urology

Johns Hopkins University School of Medicine
The Koch Cancer Research Building 1550 Orleans Street, Room 1M51 Baltimore, MD 21287

Office: 443-287-2886


Fax: 410-367-2667

Noah M. Hahn, MD was born in Valparaiso, Indiana and attended the University of Notre Dame where he graduated in 1994 with a degree in mechanical engineering.  He finished his medical school training at the Indiana University School of Medicine in 2000.  He completed a transitional year internship at Emory University in 2001, his internal medicine residency at Duke University in 2003, and his hematology and oncology fellowship at the Indiana University Simon Cancer Center (IUSCC) in 2006.  Upon completion of his fellowship training, he was appointed to the IUSCC oncology faculty and served as the leader of their prostate and bladder cancer programs.  In addition, he served as the chief scientific officer of the Hoosier Cancer Research Group (formerly the Hoosier Oncology Group) and the executive officer of the Big Ten Cancer Research Consortium.  In April 2014, Dr. Hahn joined the Johns Hopkins University School of Medicine faculty as the director of the medical oncology bladder cancer program with the academic rank of associate professor of oncology and urology.  

Dr. Hahn is an internationally recognized authority in the conduct of bladder cancer novel therapeutic clinical trials and translational investigations.  He maintains an active clinical practice and sees patients with urothelial cancers of all locations and stages including non-muscle invasive bladder cancer.  He is one of the few oncologists in the world leading a clinical trial in non-muscle invasive bladder cancer.  In addition, Dr. Hahn continues to care for patients with non-urothelial genitourinary malignancies including prostate, testicular, and other rare tumors.  Dr. Hahn's clinical and translational research interests focus on improving outcomes for patients with urothelial cancers through:

  1. The identification and validation of predictive biomarkers relevant to urothelial cancers, and
  2. The identification of novel therapeutic and preventative targets for urothelial cancer patients.   

In addition to his efforts at Johns Hopkins, Dr. Hahn serves as the bladder cancer chairman of the Eastern Cooperative Oncology Group (ECOG), co-chairs the Hoosier Cancer Research Network genitourinary oncology clinical trials working group, participates on the NCI Bladder Cancer Task Force, and serves on the scientific advisory board of the Bladder Cancer Advocacy Network. 


1994                            Cum Laude B.S., Mechanical Engineering, University of Notre Dame, Notre Dame, IN

2000                            M.D., Indiana University School of Medicine, Indianapolis, IN

6/00 – 6/01      Transitional Year Internship, Emory University, Atlanta, GA             
7/01 – 7/03      Internal Medicine Residency, Duke University, Durham, NC 
7/03 – 6/06      Hematology and Oncology Fellowship, Indiana University School of Medicine, Indianapolis, IN     
8/06 – 6/08      Clinical Investigator Training Enhancement Program (9 credit hours – Bioethics, Biostatistics, Clinical Trial Design),
Indiana University School of Medicine, Indianapolis, IN


Free Access to abstracts at PubMed

Peer-Reviewed Original Science Research Publications

  1. Hahn NM, Marsh S, Fisher W, Langdon R, Zon R, Browning M, et al, A Hoosier Oncology Group Randomized Phase II Study of Docetaxel plus Vinorelbine and Docetaxel plus Estramustine in Combination for the Treatment of Hormone Refractory Prostate Cancer with Pharmacogenetic Survival Analysis, Clin Cancer Res 2006;12(20 Pt 1):6094-9.  PMID:17062685.

  2. Hahn NM, Zon RT, Yu M, Ademuyiwa FO, Jones T, Dugan W, et al, A Phase II Study of Pemetrexed as Second-Line Chemotherapy for the Treatment of Metastatic Castrate Resistant Prostate Cancer (CRPC); Hoosier Oncology Group GU03-67, Ann Oncol 2009;20(12):1971-6.  PMID:19605506.

  3. Harrison MR, Hahn N, Pili R, Oh WK, Sweeney C, Kim KM, et al, A Phase II Study of 2-Methoxyestadiol (2ME2) NanoCrystal® Dispersion (NCD) in Patients with Taxane-Refractory, Metastatic Castrate-Resistant Prostate Cancer (CRPC), Invest New Drugs 2011;29(6):1465-74.  PMID:20499131.

  4. Flanagan J, Myers LJ, Hayes J, Hahn NM, Carney-Doebbeling C, Sweeney CJ, Presence of the metabolic syndrome is associated with shorter time to castrate resistant prostate cancer, Ann Oncol 2011;22(4):801-7.

  5. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg C, Bajorin DF, Bellmunt J, A Consensus Definition of Patients with Metastatic Urothelial Carcinoma who are Unfit for Cisplatin-based Chemotherapy, Lancet Oncology 2011; 12(3):211-214.  PMID:21376284.

  6. Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, et al, A Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab as First-Line Therapy for Metastatic Urothelial Carcinoma – Hoosier Oncology Group GU 04-75, J Clin Oncol 2011;29(12):1525-30.  PMID:21422406.

  7. Patel YR, Carr KA, Magjuka D, Mohammadi Y, Dropcho EF, Reed AD, Moore ML, Waddell MJ, Shedd-Steele R, Sweeney CJ, Hahn NM, Successful Recruitment of Healthy African-American Men to Genomic Studies from High-Volume Community Health Fairs – Implications for Future Genomic Research in Minority Populations, Cancer 2012;118(4):1075-82.  PMID:21766294.

  8. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh W, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF, Bellmunt J, Treatment of Patients with Metastatic Urothelial Cancer "Unfit" for Cisplatin-Based Chemotherapy, J Clin Oncol 2011;29(17):2432-38.  PMID:21555688.

  9. Deng X, Elzey BD, Poulson JM, Morrison WB, Ko SC, Hahn NM, Ratliff TL, Hu CD, Ionizing radiation induces neuroendocrine differentiation of prostate cancer cells in vitro, in vivo and in prostate cancer patients, Am J Cancer Res 2011;1(7):833-44.  PMID:22016831.

  10. Choueiri TK, Ross RW, Jacobus S, Vaishampayan U, Yu EY, Quinn DI, Hahn NM, Hutson TE, Sonpavde G, Morrissey SC, Buckle GC, Kim WY, Petrylak DP, Ryan CW, Eisenberger MA, Mortazavi A, Taplin ME, Rosenberg JE, Kantoff PW, A Double Blind Randomized Trial of Docetaxel plus Vandetanib versus Docetaxel plus Placebo, in Platinum-Pretreated Metastatic Urothelial Cancer, J Clin Oncol 2012;30(5):507-12.  PMID:22184381

  11. Hahn NM, Bonney PL, Dhawan D, Jones DR, Balch C, Guo Z, Hartman-Frey C, Fang F, Parker HG, Kwon EM, Ostrander EA, Nephew KP, Knapp DW, Subcutaneous 5-Azacitidine Treatment of Naturally Occurring Canine Urothelial Carcinoma: A Novel Epigenetic Approach to Human Urothelial Carcinoma Drug Development, J Urol 2012;187(1):302-9.  PMID:22099988.

  12. Dhawan D, Ramos-Vara JA, Hahn NM, Waddell J, Olbricht GR, Zheng R, Stewart JC, Knapp DW, DNMT1: An emerging target in the treatment of invasive urinary bladder cancer, Urol Oncol-Semin Orig Invest 2012; (in-press).  PMID:22609058.

  13. Cai H, Chiorean EG, Chiorean MV, Rex DK, Robb BW, Hahn NM, Liu Z, Loehrer PJ, Harrison ML, Xu Y, Elevated phospholipase A2 activities in plasma samples from multiple cancers, PLoS One 2013;8(2):e57081.  PMID:23451150.

  14. Galsky MD, Hahn NM, Powles T, Hellerstedt BA, Lerner SP, Gardner TA, Yu M, O'Rourke M, Vogelzang NJ, Kocs D, McKenney SA, Melnyk AM Jr, Hutson TE, Rauch M, Wang Y, Asmar L, Sonpavde G, Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer, Clin Genitourin Cancer 2013;11(2):175-181.  PMID:23228446.

  15. Galsky MD, Hendricks R, Svatek R, Bangs R, Hoffman-Censits J, Clement J, Dreicer R, Guancial E, Hahn N, Lerner SP, O'Donnell PH, Quale DZ, Siefker-Radtke A, Shipley W, Sonpavde G, Vaena D, Vinson J, Rosenberg J, Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group, Cancer 2013;119(11):1994-8.  PMID 23456777.

  16. Haines L, Bamias A, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, Sonpavde G, Godbold J, Oh WK, Galsky MD, The impact of gender on outcomes in patients with metastatic urothelial carcinoma, Clin Genitourin Cancer 2013;11(3):346-52. PMID 23673281.

  17. Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Godbold J, Oh WK, Bamias A, Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy, Cancer 2013;119(16):3012-9. PMID 23720216.

  18. Huang W, Williamson SR, Rao Q, Lopez-Beltran A, Montironi R, Eble JN, Grignon DJ, Idrees MT, Emereson RE, Zhou X, Zhang S, Baldridge LA, Hahn NM, Wang M, Koch MO, Cheng L, Novel markers of squamous differentiation in the urinary bladder, Hum Pathol 2013;44(10):1989-97. PMID 23806524. 

  19. Alexander RE, Montironi R, Lopez-Beltran A, Williamson SR, Wang M, Post KM, Sen JD, Arnold AK, Zhang S, Wang X, Koch MO, Hahn NM, Masterson TA, MacLennan GT, Davidson DD, Comperat E, Cheng L, EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder, Mod Pathol 2014;27(1):107-12. PMID:23887300. 

  20. Hahn NM, Yiannoutsos CT, Kirkpatrick K, Sharma J, Sweeney CJ, Failure to Suppress Markers of Bone Turnover on First-Line Hormone Therapy for Metastatic Prostate Cancer Is Associated with Shorter Time to Skeletal-Related Event, Clin Genitourin Cancer 2014;12(1):33-40.  PMID 24126237.

  21. Galsky MD, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, Sonpavde G, Godbold J, Oh WK, Bamias A, Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer, Urol Oncol 2014;32(1):e15-21. PMID 23428534.

  22. Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Pond G, Godbold J, Oh WK, Bamias A, Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy, Urol Oncol 2014;32(1):e1-8. PMID 24055428.

  23. Kaimakliotis HZ, Monn MF, Cary KC, Pedrosa JA, Rice K, Masterson TA, Gardner TA, Hahn NM, Foster RS, Bihrle R, Cheng L, Koch MO, Plasmacytoid variant urothelial bladder cancer: Is it time to update the treatment paradigm?, Urol Oncol 2014; (in-press) PMID:24954925.


  •    Under Construction

Awards & Honors

ASCO Leadership Development Program